Professor of Radiation Oncology and Molecular Radiation Sciences, Professor of Oncology, Professor of Urology, Johns Hopkins University School of Medicine; Director, Department of Radiation Oncology and Molecular Radiation Sciences, Radiation Oncologist -
Radiation Oncology
Dr. Theodore L. Deweese, MD
|
|
Give Review
Theodore Deweese practices Radiation Oncology. He researched medicine at University of Colorado Denver School of Medicine. University of Colorado Denver School of Medicine is one of the top medical schools in the US. University of Colorado Denver School of Medicine has a rank of 35 in research and a 8 in primary care He over the years received 5 awards: "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area" and "Top Doctors:Washington-Baltimore". Theodore Deweese is a published doctor. He published 101 publications, including: 'Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.
- Bromopyridone Nucleotide Analogues, Anoxic Selective Radiosensitizing Agents That Are Incorporated in DNA by Polymerases.
- A Roadmap for a New Academic Pathway for Global Radiation Oncology.
- Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer.
- In reply to Raince and Bloom and Olson.
- Low Interrater Reliability in Grading of Rectal Bleeding Using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity Scales:...
- Patterns of care among patients receiving radiation therapy for bone metastases at a large academic institution.
- A streamlined failure mode and effects analysis.
- Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate.
- Development and Screening of a Series of Antibody-Conjugated and Silica-Coated Iron Oxide Nanoparticles for Targeting the Prostate-Specific Membrane Antigen.
- Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor.
- Irreversible Inhibition of DNA Polymerase β by Small-Molecule Mimics of a DNA Lesion.
- Combined Treatment Effects of Radiation and Immunotherapy: Studies in an Autochthonous Prostate Cancer Model.
- Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancer.
- Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.
- The effect of anterior proton beams in the setting of a prostate-rectum spacer.
- A Multi-institutional Clinical Trial of Rectal Dose Reduction via Injected Polyethylene-Glycol Hydrogel During Intensity Modulated Radiation Therapy for Prostate Cance...
- Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
- Accuracy of marketing claims by providers of stereotactic radiation therapy.
- An Evaluation of Departmental Radiation Oncology Incident Reports: Anticipating a National Reporting System.
- The effect of cell-cluster size on intracellular nanoparticle-mediated hyperthermia: is it possible to treat microscopic tumors?
- Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate radiation.
- Preliminary study of injury from heating systemically delivered, nontargeted dextran-superparamagnetic iron oxide nanoparticles in mice.
- High-Grade Prostatic Adenocarcinoma Present in a Single Biopsy Core as Associated With Increased Extraprostatic Extension, Seminal Vesicle Invasion, and Positive Surgi...
- Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
- Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.
- Clinical results of a pilot study on stereovision-guided stereotactic radiotherapy and intensity modulated radiotherapy.
- Effects of prostate-rectum separation on rectal dose from external beam radiotherapy.
- Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.
- Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
- Evaluation of safety in a radiation oncology setting using failure mode and effects analysis.
- Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.
- Evaluating advanced technologies in radiation oncology: when and how should randomized trials be done?
- A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
- DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.
- Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.
- High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities.
- Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
- Clinical practice. Localized prostate cancer.
- Defining the appropriate measure of success for adjuvant radiation following prostatectomy.
- Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.
- Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
- Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
- ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
- Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiothe...
- Radiation therapy for prostate cancer: the role for dose escalation.
- Can PSA nadir predict prostate cancer outcomes following radiotherapy?
- Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect".
- Radiation dose escalation as treatment for clinically localized prostate cancer: is more really better?
- Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis.
- Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
- Evasion of early cellular response mechanisms following low level radiation-induced DNA damage.
- The role of inflammation in the pathogenesis of prostate cancer.
- Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: the new standard?
- Hematopoietic progenitor stem cell homing in mice lethally irradiated with ionizing radiation at differing dose rates.
- Making the right choices for radiation therapy.
- Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
- Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment.
- Defective human MutY phosphorylation exists in colorectal cancer cell lines with wild-type MutY alleles.
- Two secondary malignancies after radiotherapy for seminoma: case report and review of the literature.
- Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.
- Inadequate "caretaker" gene function and human cancer development.
- Dosimetric and technical considerations for interstitial adenoviral gene therapy as applied to prostate cancer.
- 8-Hydroxyguanosine repair is defective in some microsatellite stable colorectal cancer cells.
- The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
- Salvage radiotherapy for rising or persistent PSA after radical prostatectomy.
- The diet, prostate inflammation, and the development of prostate cancer.
- System for robotically assisted prostate biopsy and therapy with intraoperative CT guidance.
- Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation.
- Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.
- Radiation-induced impairment of bone healing can be overcome by recombinant human bone morphogenetic protein-2.
- Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) prog...
- Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer.
- Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure.
- Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation.
- Prostate-specific antigen and other markers of therapeutic response.
- Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy.
- Radiation myositis.
- Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate.
- Feasibility of ablating normal renal parenchyma by interstitial photon radiation energy: study in a canine model.
- Multimodality therapy for the treatment of muscle-invasive bladder cancer.
- Temporal CT changes after hepatic and renal interstitial radiotherapy in a canine model.
- A dose texture plot in a moving frame as a new planning tool for single-plane implants in HDR brachytherapy.
- The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention.
- Oxidative stress in chemoprevention trials.
- The molecular pathogenesis of prostate cancer: focus on the earliest steps.
- CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.
- A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment.
- Radiation therapy for the treatment of locally advanced and metastatic prostate cancer.
- Acute and late radiotherapy toxicity in patients with inflammatory bowel disease.
- A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
- GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells.
- Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment wit...
- Preneoplastic prostate lesions: an opportunity for prostate cancer prevention.
- The international cancer expert corps: a unique approach for sustainable cancer care in low and lower-middle income countries.
- Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer.
- Phase I trial with a combination of docetaxel and ¹âµ³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
- Safety strategies in an academic radiation oncology department and recommendations for action.
- Targeting of mutant hogg1 in mammalian mitochondria and nucleus: effect on cellular survival upon oxidative stress.
- Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.
Schools
University Of Colorado School Of Medicine
Franklin Square Hospital
Johns Hopkins University
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
Education
-
Johns Hopkins University -
University of Colorado Denver School of Medicine
Hospital
-
Howard County General Hospital -
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1528003373 | |
| NPPES Provider LastName | DEWEESE | |
| NPPES Provider FirstName | THEODORE | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 26.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528003373 |
| Last Name Of The Provider | DEWEESE |
| First Name Of The Provider | THEODORE |
| View All |
Similar Doctors
|
|
Dr. Young Kwok, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randi J. Cohen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cardella W. Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Nichols, MD |
|
|
Dr. Sara R. Alcorn, MD |
|
|
Dr. Alexander S. Engelman, MD |
|
|
Dr. Michael S. Chung, MD |
|
|
Dr. Adam S. Reese, MD |
|
|
Pradip P. Amin, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason K. Molitoris, MD |
|
|
Dr. Robert C. Susil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Enid Choi, MD |